Overview

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this study is to support the development of a DLX105 topical formulation for the indication mild to moderate psoriasis vulgaris.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Delenex Therapeutics AG